Introduction
Inhaled b 2 -agonists are used in the treatment of asthma both as rescue medication and as regular prophylaxis. They are divided into two groups: short-acting and long-acting b 2 -agonists. Only the short-acting b 2 -agonists are recommended to be used as needed for acute symptom relief in patients with mild to more severe asthma (1) . The commonly used inhaled short-acting b 2 -agonists have a disadvantage in having a duration of bronchodilation of only 4±6 h (2) . As the long-acting inhaled b 2 -agonists have a duration of action of at least 12 h (3,4), it would be bene®cial to asthmatic patients if these drugs also could show an onset of action comparable to that of the shortacting inhaled b 2 -agonists.
Most of the previous observations on the onset of action of formoterol have been made in comparison with the other long-acting b 2 -agonists approved for regular daily use, salmeterol. Salmeterol has been shown to have a slow onset of action, whereas formoterol administered via a pMDI (5) and via Turbuhaler 1 (6,7) has been shown to have a fast onset of action. One study has compared formoterol administered via a pMDI to the short-acting b 2 -agonists salbutamol (8) . This study showed that the onset of the bronchodilating action of formoterol was roughly similar to that of salbutamol.
The aim of this study was to investigate the bronchodilating eect within the ®rst 30 min after inhalation of single doses of formoterol administered via the inspiratory¯ow driven multidose dry powder inhaler Turbuhaler. The delivered doses 4?5 and 9 mg were compared with salbutamol 100 and 200 mg delivered via a pMDI and placebo in adult patients with mild to moderate asthma.
A few studies have also made a comparison between the onset of action of formoterol dry powder (Aerolizer 1 , Novartis) and salbutamol in adult asthmatics (9±10). In none of these studies a comparison has been made in the same way as in the present day study i.e. measuring FEV 1 already within the ®rst 3 min after inhalation.
Patients and Methods

PATIENTS
Patients of either gender aged 18 years or older were included. They all had a diagnosis of asthma in a stable condition with a minimum duration of 6 months. Only nonsmokers or ex-smokers, who had stopped smoking at least 6 months prior to the ®rst visit were to be included. They should have a baseline FEV 1 40% of predicted normal value and a FEV 1 of at least 1?5 l and a reversibility of at least 15%, 15 min after inhalation of 0?5 mg terbutaline sulphate (Bricanyl 1 Turbuhaler). Patients who showed any signs of clinically relevant concomitant diseases were not included.
Prior to each study day, the patients discontinued inhaled short-acting b 2 -agonists for 6 h and inhaled ipratropium bromide for 8 h. Disodium cromoglycate, anti-histamines including ketotifen, inhaled and nasal glucocorticosteroids (GCS) were permitted during the study, provided that the doses were kept constant during 4 weeks prior to and throughout the study. Oral b 2 -agonists, inhaled long-acting b 2 -agonists, oral GCS, parenteral GCS, xanthines and oral adrenergics were not allowed during the study.
STUDY DESIGN
The study was multi-centred and placebo-controlled with a double-blind, double-dummy and cross-over design. The study consisted of one screening visit and ®ve study visits. At the study visits, eligible patients were given either formoterol 4?5 mg or 9 mg via Turbuhaler, salbutamol 100 mg or 200 mg via a pMDI or placebo as single doses. On each occasion the patients inhaled one dose from two identical Turbuhaler inhalers and one dose from two pMDIs of the same appearance to preserve the blinding of the study. The doses used in the study are those recommended by the manufacturers for salbutamol pMDI and formoterol Turbuhaler. All four inhalations were performed within 1 min. The inhalations also had to be performed between 07?00 and 10?00 hours and varying at most by 30 min between visits for an individual patient and separated by a minimum of two days washout. Baseline FEV 1 had to be within12% of the FEV 1 measured at the screening visit. If not, the patients were asked to come back another day. Three such attempts were allowed. The minimum duration of the study was estimated to be 12 days, including a post-study telephone contact for follow-up of adverse events.
Patients were randomized in Latin squares of size ®ve. Strati®cation was made so that patients with even numbers inhaled from the Turbuhaler ®rst and patients with odd numbers inhaled from the pMDI ®rst. In order to ensure a correct inhalation technique, all patients received instructions on how to use both the Turbuhaler and pMDI at their ®rst visit. At all visits, the patients also practised the inhalation technique with placebo inhalers and all study medication was taken under direct supervision of the investigational team.
The study was approved by the National Health Authorities in the Czech Republic and the local ethics committees. The patients gave their informed consent before enrolment in the study. The study was performed in accordance with the principles stated in the Declaration of Helsinki.
ONSET OF ACTIONÐBRONCHODILATING EFFECT
For determination of onset of action, FEV 1 was measured before and 1, 3, 5, 7, 10, 15, 20, 25 and 30 min after completed inhalation of the investigational products. The higher value out of two measurements, recorded by a Vitalograph 1 Alpha (Vitalograph Inc., Buckingham, England), was used. All measurements were made with the same spirometer for each patient.
ONSET OF ACTIONÐSUBJECTIVE EXPERIENCE
To evaluate the onsets of action, as judged by the patients, a question was asked 3 min after inhalation at every study visit. The question was:`Was the medication eective?'. The patients were instructed to preferably answer yes or no to the question. If they answered`not sure',`don't know' etc, the answer was registered as`no'.
STATISTICAL METHODS
Onset of action measured as FEV 1
The primary variable was the FEV 1 -value at 3 min after inhalation of study drug. It was compared between treatments by a multiplicative analysis of variance (ANO-VA) model with patient, visit and treatment as ®xed factors and the pre-dose FEV 1 values as a covariate. The time to response, where response was de®ned as a 15% increase in FEV 1 from the pre-inhalation value, was also compared between the active treatments, using survival analysis.
Dierences in the time-response pro®le were investigated with an ANOVA model including patient, visit, treatment, time and interaction treatment by time as factors and the pre-dose FEV 1 values as a covariate. In this analysis, only the high dose of each substance was included.
Correlation between FEV 1 and the response experienced by the patients 3 min after inhalation
To investigate the correlation between the response measured as FEV 1 3 min after drug administration and the answer to the above question, a mixed eects logistic regression model was applied using the General Estimating Equations (GEE) technique.
Results
PATIENTS
Thirty-six Caucasian patients, of whom 16 were women, with a mean age of 34 years (range 18±64 years) participated in the study. They showed a mean baseline FEV 1 of 2?75 l (1?60±5?19 l) at study entry, which corresponded to a mean FEV 1 in % of predicted normal values of 73?8% (46±106%). They also exhibited a mean reversibility of 24?2% (14?6±47?1%).
Thirty-two patients were on regular treatment with inhaled GCS, since at least 1 month prior to enrolment. Twenty-six patients had one or more short-acting b 2 -agonists, ®ve patients used anti-histamines, two patients nasal GCS, and one patient anti-cholinergics. Twenty-nine patients had never smoked, seven patients were previous smokers. Thirty patients had extrinsic asthma, two intrinsic asthma, one chronic obstructive asthma and three unspeci®ed asthma. The duration of asthma ranged between 1 and 47 years. All 36 patients were enrolled at ®ve dierent centres in Czech Republic.
ONSET OF ACTIONÐBRONCHODILATING EFFECT
All enrolled patients completed the study and they were all considered fully eligible. Figure 1 illustrates the mean value FEV 1 curves, where the FEV 1 -values are given as percentage change from baseline.
The FEV 1 value measured 3 min after inhalation revealed no dierences between active treatments. All active treatments gave a statistically signi®cantly higher bronchodilating eect than placebo; 10?0, 11?4% for salbutamol 100 and 200 mg and 11?7, 11?8% for formoterol 4?5 and 9 mg, (P50?001 in all cases). The relative dierence vs. placebo remained throughout the 30 min of measurement for all active treatments except low dose salbutamol. A time-trend test including the high dose of formoterol and salbutamol was highly non-signi®cant (P=0?94).
The median time to response ranged between 2?8 min (formoterol 9 mg) and 5?3 min (salbutamol 200 mg). No dierence in this parameter between formoterol and salbutamol was found. Results are given in Table 1 .
ONSET OF ACTIONÐSUBJECTIVE EXPERIENCE
The increase in FEV 1 was generally much higher for the patients who answered`yes' to the question 3 min after inhalation of study drug, than for the patients who answered`no'. Mean increase in FEV 1 (%) was 18?1 in the`yes' group and 5?6 in the`no' group, as shown in Table 2 .
Correlation between FEV 1 and the response experienced by the patients 3 min after inhalation 
Discussion
It is a common opinion that short-acting b 2 -agonists are associated with a more rapid onset of action than longacting b 2 -agonists (11) . In internationally accepted guidelines, short-acting b 2 -agonists are classi®ed as symptom relievers' and are recommended to be used as needed in patients with mild to more severe asthma or to prevent obstruction induced by exercise or allergen provocation. The long-acting b 2 -agonists are only recommended for regular use in patients whose symptoms are not controlled with inhaled GCS (1). In the present study, no dierences were found between formoterol and salbutamol regarding the bronchodilating eect 3 min after inhalation and in the time to response. These ®ndings are in line with the results from other studies, in which a comparison regarding the onset of action between formoterol dry powder and salbutamol in adults has been made. However, in these studies increase in FEV 1 from pre-to 5 min post-dose (9) or increase in speci®c airway conductance (sGaw) (10) have been used. The same results have also been shown in a study evaluating the speeds of action of formoterol and salbutamol dry powder in reversing methacholine-induced bronchoconstricton (12) . No other study, that we are aware of, has compared the onset of action between formoterol Turbuhaler and salbutamol pMDI.
The current data thus show that formoterol Turbuhaler has a rapid onset of action, comparable to that of the shortacting b 2 -agonist salbutamol, at recommended doses. These data indicate that there is need for a revision of the opinion that short-acting is equal to fast onset and long-acting is equal to slow-acting. Maybe a better classi®cation would be to describe the b 2 -agonists as fast-and slow-acting with dierent duration of action.
The fast onset of action of formoterol via Turbuhaler, as shown in the present and previous studies (6,7) would make it possible to use it as needed for symptom relief in patients with mild to moderate asthma. The use of formoterol Turbuhaler on demand, in patients with moderate asthma, has been evaluated in a recent study (13) . In this study, formoterol Turbuhaler prolonged the time to ®rst asthma exacerbation and improved asthma control compared with terbutaline Turbuhaler.
One must also consider that true p.r.n. use of long-acting b 2 -agonist could lead to a use of high doses in the case of an acute bronchoconstriction. However the use of high doses of formoterol has been documented in previous studies. One study compared formoterol Turbuhaler to terbutaline Turbuhaler in high doses (14) . The results of this study showed that daily doses up to and including 120 mg formoterol (corresponding to 90 mg delivered dose) were safe and well tolerated in patients with chronic asthma and without concomitant ischaemic heart diseases, using (15) . The results from this study also showed that formoterol Turbuhaler in doses up to 90 mg were safe and well tolerated. The data mentioned above together with the data from the present study makes formoterol Turbuhaler a candidate for true p.r.n. use. Further studies where formoterol Turbuhaler is given p.r.n. compared to a short-acting b 2 -agonist given p.r.n., in patients with mild persistent asthma, would therefore be of great interest.
In addition to the objectively measured onset of action, the subjective onset as judged by the patients was evaluated. No other study has compared the correlation between the subjective and objective time to onset of action, although one non-placebo-controlled study has made a comparison regarding the duration of eect after inhalation of formoterol and salbutamol. This study indicated a good correlation between subjective and objective duration of eect (16) . Data from the current study showed a positive correlation between the subjective and the objective onset of action. Thus, the fast onset of action of formoterol Turbuhaler measured by FEV 1 3 min after inhalation was also experienced by the patients, further indicating that formoterol Turbuhaler given p.r.n. could be appreciated by the patients.
In conclusion we have demonstrated that formoterol administered via Turbuhaler at recommended doses, has as rapid an onset of action as salbutamol administered via pMDI at recommended doses.
